Navigation Links
Genomic Health Announces Data Confirming Manual Microdissection of Biopsy Cavities Is Essential for Accurate Recurrence Risk Assessment in Early-Stage Breast Cancer Patients
Date:10/9/2009

inical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. In addition to the widely adopted Oncotype DX breast cancer test, Genomic Health is preparing to launch its Oncotype DX colon cancer test in early 2010. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the applicability of clinical study results to actual outcomes, the belief that manual microdissection should be practiced as a part of any molecular breast cancer diagnostic platform that assesses risk of recurrence by examination of tumor tissue, the belief that expert pathologists play a critical role in working with the clinical reference laboratory to provide the most accurate molecular assessment of individual tumors so that physicians and patients can make well-informed individual treatment decisions, and the company's plans to commercialize a test for colon cancer and the proposed timing of such commercialization. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risk that we may not obtain or maintain sufficient levels of reimbursement for our tests; the risks and uncertainties associated with the regulation of our tests; the applicability of clinical study results to actual outcomes; the risks and poten
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Microarray provides 3 genomic guides to breast cancer treatment decisions
3. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
4. Genomic Health to Present at ThinkEquity Partners Fifth Annual Growth Conference
5. Genomic profiling of lung tumors helps doctors choose most effective treatment
6. Genomic technologies to identify toxic chemicals should be developed
7. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
8. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
9. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test:
10. Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders
11. Genomic Health to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... 30, 2015 , ... Between 2012 and 2014 HIV infection rates rose from ... on June 17th. Those untreated heroin use disorders share their needles and spread the ... needles throughout the community. Ultimately Florida’s HIV infection rates have bolstered to 23 percent ...
(Date:7/30/2015)... ... 30, 2015 , ... Ocean Hills Recovery has officially been accredited by CARF ... No recommendations means CARF found no areas in the OHR program that needed improvement, ... of all facilities receive. In addition, Ocean Hills was granted the maximum certification period ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... Administration (DEA) Acting Administrator Chuck Rosenberg’s announcement of the reinstitution of National Prescription ... Saturday, September 26, 2015 from 10:00 AM to 2:00 PM local time. On ...
(Date:7/30/2015)... ... July 30, 2015 , ... The Tisch Cancer ... Designation , The Tisch Cancer Institute (TCI) at the Icahn School of Medicine ... TCI joins an elite group of 69 cancer institutions nationwide that have earned ...
(Date:7/30/2015)... , ... July 30, 2015 , ... InventHelp, ... Texas, has designed a personal-care device that makes it easy to apply lotion or ... eliminate the need for assistance when applying lotion or medication to the back, and ...
Breaking Medicine News(10 mins):Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 2Health News:HIV Rates Rise in S. Florida, Harbor Village Comments on Health News Florida's Recent Article 3Health News:Ocean Hills Recovery Receives Accreditation from CARF International 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 2Health News:AAPCC Supports National Prescription Drug Take-Back Day 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:InventHelp® Client Patents “My Back Buddy” – Device Could Apply Lotion to Hard-to-Reach Areas Easily 2
... been characterized as the most materialistic generation in history: ... owning luxury handbags and the latest technology devices. ... of teen materialism. In fact, research suggests that parents ... therefore, highly materialistic parents and peers are likely to ...
... ... headquartered in Nashville must pay $19.4 million plus interest to the United States government after ... , ... 2010 -- United States District Court Judge William J. Haynes, Jr. issued an order on ...
... ... Center School of Medicine has designed a first-of-its-kind program to alleviate ... Track (FMAT), has been approved by the Liaison Committee for Medical ... will complete their training one year earlier than students in the ...
... ... a new effort by Congress to reduce pharmacy choices, arbitrarily set prices, ... program. FEHBP enrollees feel that OPM does a great job managing ... the program by forcing OPM to change FEHBP’s pharmacy benefits. This was ...
... for some patients with operable disease, review finds , ... for patients with operable non-small cell lung cancer, say ... meta-analysis of 34 studies involving almost 8,500 patients (and ... years was 64 percent for patients who had chemotherapy ...
... Tuesday, President Obama signed into law U.S. health care ... affect them, their families, and businesses. The ... 2006 legislation in Massachusetts requiring all adults in the ... mandate. A new article from The Milbank Quarterly ...
Cached Medicine News:Health News:Counteracting teens' logo lust 2Health News:Fresenius Medical Holdings, Inc. Ordered To Pay $19.4 Million For Fraudulent Medicare Claims 2Health News:Fresenius Medical Holdings, Inc. Ordered To Pay $19.4 Million For Fraudulent Medicare Claims 3Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 2Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 3Health News:Primary Care Physician Shortage: Texas Tech University Health Sciences Center Has the Solution 4Health News:PCMA: Federal Enrollees Don't Want Congress to Reduce Pharmacy Choices, Impose Price Controls in FEHBP 2Health News:Chemo May Boost Survival After Lung Cancer Surgery 2Health News:Massachusetts health care reform reviewed as a model for national plan 2
(Date:7/30/2015)... ATLANTA , July 30, 2015  Big ... real-time predictive analytics technology, announces it is working ... (IoT) solutions for the new Lockheed Martin Healthcare ... of leading health information technology providers, medical technology ... foster collaboration and innovation to improve care in ...
(Date:7/30/2015)... July 30, 2015  Cleave Biosciences today announced ... has granted the company a key patent providing ... molecule CB-5083. This newly issued patent, ... p97," U.S. 9,062,026, allows for claims on the ... selective oral inhibitor of p97, a critical enzyme ...
(Date:7/30/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... treat obesity, metabolic diseases and other gastrointestinal disorders, today ... Thursday, August 6, 2015, at 11:00 AM Eastern Time ... June 30, 2015, and to provide an update on ... via the Maestro® System. Conference Call Details ...
Breaking Medicine Technology:Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 2Big Cloud Analytics Develop Internet of Things (IoT) Solutions with Intel Supporting Launch of Lockheed Martin Healthcare Technology Alliance 3EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3
... 11, 2011 CrystalGenomics, Inc., a biopharmaceutical company with ... draft Clinical Study Report (CSR) from CG400549,s Phase I ... CG400549 is a potential first-in-class antibiotic candidate ... enzyme in generating bacterial membrane and has a novel ...
... Corporation (NASDAQ: LIFE ) announced today that ... all of the outstanding 3.25% Convertible Senior Notes due ... As of May 6, 2011 there was $350,000,000 in ... The redemption notice provided includes CUSIP Numbers: 46185RAL4 and ...
Cached Medicine Technology:CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study 2Life Technologies Announces Redemption of 3.25% Convertible Senior Notes Due 2025 2
... Lensmeter is designed for fast and easy ... Auto mode, the readings are automatically held ... lenses are automatically detected. The sophisticated alignment ... lens. The TL-2000A has been designed with ...
The Kowa Pro-lll is Kowas' flagship camera....
The new CR6-45NM non-mydriatic retinal camera is an ideal diagnostic tool for ophthalmologists, optometrists and other medical professionals, especially when it comes to detecting and monitoring diab...
FF 450plus IRu Fundus camera with Visupac / System 431. Digital results in all capture modes and unlimited Visupac software....
Medicine Products: